This market resolves to Yes if the immunotherapy clinical trial for treatment-resistant depression, as reported by *JAMA Psychiatry*, publicly announces significant positive results by June 30, 2026. Significant positive results imply that the treatment is statistically proven to improve patient outcomes compared to the control group.